| Date | Thursday, April 1 | Friday, April 2 | Saturday, April 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Room | R1 | R2 | R3 | R1 | R2 | R3 | R4 | R1 | R2 | R3 |
| 07:30-08:00 | Business Meeting (07:30-08:30) |
|||||||||
| 08:00-08:30 | Registration | Registration | Registration | |||||||
| 08:30-09:00 | Opening Remark (08:50-09:00) | Working party Report (08:30-09:00) |
||||||||
| 09:00-10:30 | [SS01] Acute Lymphoblastic Leukemia |
[SS02] B-Cell Lymphoma |
[ES01] Myelodysplastic Syndrome |
[JS04] ASH-KSH Joint Symposium |
[SS06] Thrombotic issues in hematology |
[ES03] Lymphoma |
[SS10] Immunotherapy/ Transplantation |
[SS11] Pediatric Disease |
[SS12] T-Cell Lymphoma /HD |
|
| 10:30-11:15 | [PL01] Cutting Edge of Emerging Therapies |
[PL02] Clinical Hematology Lecture |
[PL03] Genomics in Hematologic Malignancies |
|||||||
| 11:15-11:30 | Break | Break | Break | |||||||
| 11:30-12:10 | [SY01] Astellas |
[SY02] Sanofi-Aventis |
[SY03] BMS-Celgene |
[SY04] Handok |
[SY05] Roche |
[SY06] Amgen |
[SY07] Janssen |
[SY08] Novartis |
[SY09] Kyowa Kirin |
[SY10] Takeda |
| 12:10-12:55 | E-poster Exhibition (12:10-12:55) | E-poster Exhibition (12:10-12:40) | Award Ceremony & Closing (12:10-12:55) | |||||||
| 12:55-14:25 | [AS01] Asian Session 1 (12:55-13:55) |
[JS01] KAI-KSH Joint Session (12:55-14:25) |
[SS0 3] Advances in Technology (12:55-14:25) |
Oral Presentation (12:40-13:40) |
||||||
| 14:25-14:40 | Break (14:25-14:40) | Break (13:40-13:55) | ||||||||
| Presidential Symposium (13:55-14:40) | ||||||||||
| 14:40-16:10 | [AS02] Asian Session 2 (14:40-15:40) |
[JS02] KOGO-KSH Joint Session (14:40-16:10) |
[SS04] Stem Cell: Biology and Therapeutic Target (14:40-16:10) |
[MS01] MOU Country Session (14:40-15:40) |
[SS07] Benign Hematology (14:40-16:10) |
[ES04] Myeloproliferative Neoplasm (14:40-16:10) |
||||
| 16:10-16:25 | Break | Break | ||||||||
| 16:25-17:55 | [JS03] EHA-KSH Joint Symposium 1 - Basic (16:25-18:05) |
[SS05] Multiple Myeloma |
[ES02] Rare Hematologic Disorders |
[JS05] EHA-KSH Joint Symposium 2 -Clinical Translational (16:25-18:05) |
[SS08] Supportive Care |
[SS09] Bone Marrow Failure Syndrome |
||||
| Date | Thursday, April 1, 2021 | ||
|---|---|---|---|
| Room | ROOM 1 | ROOM 2 | ROOM 3 |
| 08:00-09:00 | Registration | ||
| 08:50-09:00 | Opening | ||
| 9:00-10:30 | [SS01] Acute Lymphoblastic Leukemia | [SS02] B-Cell Lymphoma | [ES01] Myelodysplastic Syndrome |
| Contemporary Treatment of Pediatric Ph+ ALL Kirk Schultz, Canada |
Diffuse Large B-cell Lymphoma: at the crossroad of Genetics and Epigenetics Laura Pasqualucci, USA |
Myelodysplastic Syndrome and Overlap Syndrome Yoon Hwan Chang, Korea |
|
| Current Treatment Approaches to Newly Diagnosed Adult ALL Daniel Joseph DeAngelo, USA |
Immunotherapy for Hodgkin Lymphoma John Kuruvilla, Canada |
MDS with Genetic Predisposition Meerim Park, Korea |
|
| Results of High Risk and Novel Subtypes of Pediatric ALL in Japan Katsuyoshi Koh, Japan |
Optimal Treatment of High-Risk Aggressive B-Cell Lymphoma Lorenz Trümper, Germany |
Diagnosis and Treatment of Chronic Myelomonocytic Leukemia Jihyun Kwon, Korea |
|
| 10:30-11:15 | Plenary Lecture I - Cutting Edge of Emerging Therapies | ||
| Clonal Hematopoiesis and the Origin of Hematologic Malignancies Benjamin Ebert, USA |
|||
| 11:15-11:30 | Break | ||
| 11:30-12:10 | [SY01] Satellite Symposium 1 | [SY02] Satellite Symposium 2 | [SY01] Satellite Symposium 3 |
| New Treatment Option for FLT3 mutant AML Alexander Edward Perl, USA
Sponsored by
|
Latest Treatment for Hemophilia A and B in Japan Keiji Nogami, Japan
Sponsored by
|
Optimal Treatment with IMiDs in Newly Diagnosed Multiple Myeloma Pieter Sonneveld, The Netherlands
Sponsored by
|
|
| 12:10-12:55 | E-poster Exhibition | ||
| 12:55-14:25 | [AS01] Asian Session I -Recent Therapeutic Approaches in CML(12:55-13:55) |
[JS01] KAI-KSH Joint Session | [SS03] Advances in Technology |
| From Korean Perspective Young Rok Do, Korea |
Regulating Regulatory T Cells for Enhancement of Cancer Immunotherapy Sang-Jun Ha, Korea |
Incorporating Genetics into Clinic Elli Papaemmanuil, USA |
|
| From Chinese Perspective Qian Jiang, China |
IL-17-Producing Cells in Tumor Yeon Seok Chung, Korea |
Intelligent Image-Activated Cell Sorting: Principles and Application to Hematology Akihiro Isozaki, Japan |
|
| From Japanese Perspective Shinya Kimura, Japan |
Pro-Inflammatory Cytokines in Graft-Versus-Host Disease (GVHD) Young-Woo Jeon, Korea |
HARMONY: A Big Data for Better Outcomes Project in Hematological Malignancies Jesús María Hernández Rivas, Spain |
|
| Harnessing Adaptive Natural Killer Cells for Immunotherapy in Multiple Myeloma Hyunsoo Cho, Korea |
|||
| 14:25-14:40 | Coffee Break | ||
| 14:40-16:10 | [AS02] Asian Session II -Updates of Hematologic Disease in Asian Population (14:40-15:40) |
[JS02] KOGO-KSH Joint Session | [SS04] Stem Cell: Biology and Therapeutic Target |
| Management of TDT and NTDT Thalassemia in Indonesia Tubagus Djumhana Atmakusuma, Indonesia |
Single Cell RNA Sequencing Reveals Transcriptional Programs Associated with Myeloma Progression Hae-Ock Lee, Korea |
Discovery of New Regulators in Stem Cells and Malignancies Dongjun Lee, Korea |
|
| Hemophilia Treatment in Singapore Tien Sim Leng, Singapore |
Multi-Omics Analysis and Modeling of DNA Methylation in Cancer Sun kim, Korea |
AMD1 Is Essentially Required in Leukemic Stem Cells Hyog Young Kwon, Korea |
|
| Thalassemia Treatment in Malaysia Jameela Sathar, Malaysia |
Clinical Application of Next-Generation Sequencing in Acute Myeloid Leukemia Jae-Sook Ahn, Korea |
BCL-2 as a Stem Cell Target in AML Daniel A. Pollyea, USA |
|
| Challenges in the Introduction of Next-Generation Sequencing for Diagnostics of Hematologic Malignancies Seung-Tae Lee, Korea |
|||
| 16:10-16:25 | Break | ||
| 16:25-17:55 | [JS03] EHA-KSH Joint Symposium 1 - Basic - (16:25-18:05) |
[SS05] Multiple Myeloma | [ES02] Rare Hematologic Disorders |
| Clonal Evolution under IDH Inhibitor Therapy in AML Lynn Quek, UK |
Novel Strategies to Overcome Relapsed/Refractory Multiple Myeloma Suzanne Trudel, Canada |
Molecular Diagnosis of Thalassemia Jee-Soo Lee, Korea | |
| TBD Kimmo Porkka, Finland |
MRD Negativity - The Foremost Important Goal of Myeloma Treatment? Bruno Paiva, Spain |
Current Understanding and Treatment Strategies of Langerhans Cell Histiocytosis Kyung-Nam Koh, Korea | |
| TET Loss-of-Function in Malignant Hematopoiesis Myunggon Ko, Korea |
Primary Amyloidosis Ki Hyun Kim, Korea | Pathogenesis and Treatment Overview of Secondary Hemophagocytic Lymphohistiocytosis Yu Ri Kim, Korea | |
| Novel Small Molecule Drug Discovery to Override NRAS-mutated AML Taebo Sim, Korea | |||
| Date | Friday, April 2, 2021 | |||
|---|---|---|---|---|
| Room | ROOM 1 | ROOM 2 | ROOM 3 | ROOM 4 |
| 08:00-09:00 | Registration | |||
| 9:00-10:30 | [JS04] ASH-KSH Joint Symposium - ALL - |
[SS06] Thrombotic issues in hematology | [ES03] Lymphoma Novel diagnosis and management of B-cell lymphoma |
|
| Epigenetic Control in T-Cell Acute Lymphoblastic Leukemia Marjorie Brand, Canada |
Direct Oral Anticoagulants for the Treatment of VTE in Cancer Patients Marc Carrier, Canada |
B-Cell Lymphoma's New Genomics Youngil Koh, Korea |
||
| TBD | Thrombotic Thrombocytopenic Purpura: Moving Towards a More Targeted Treatment and Follow-up Spero Cataland, USA |
Immuno-Oncology for B-Cell Lymphomas Yoon Seok Choi, Korea |
||
| Current Concepts in the Management of Relapsed/Refractory ALL in Korean Joon Ho Moon, Korea |
Post-Transplant Thrombotic Microangiopathy Vahid Afshar-Kharghan, USA |
Novel Combination Immunochemotherapy beyond CD20 Jun Ho Yi, Korea |
||
| Pediatric Acute Lymphoblastic Leukemia in Korea Hyoung Jin Kang, Korea |
||||
| 10:30-11:15 | Plenary Lecture II - Clinical Hematology Lecture | |||
| Genetic Landscape of Lymphoma and Novel Treatment Approaches Wyndham Hopkins Wilson, USA |
||||
| 11:15-11:30 | Coffee Break | |||
| 11:30-12:10 | [SY04] Satellite Symposium 4 | [SY05] Satellite Symposium 5 | [SY06] Satellite Symposium 6 | [SY07] Satellite Symposium 7 |
| Ravulizumab: Next Generation of C5 Inhibitor for the Standard Care of PNH Jin Seok Kim, Korea
Sponsored by
|
DLBCL Treatment Strategy in Relapsed and Refractory Setting - Role of Polatuzumab Laurie Sehn, Canada
Sponsored by
|
Treatment Strategies in Relapsed and Refractory Multiple Myeloma: A Focus on Sequential Treatment for Survival Benefit Joseph Mikhael, USA
Sponsored by
|
When and How to Treat Front-Line Chronic Lymphocytic Leukemia? Anthony Mato, USA
Sponsored by
|
|
| 12:10-12:40 | E-poster Exhibition | |||
| 12:40-13:40 | ORAL PRESENTATION | |||
| 13:40-13:55 | Break | |||
| 13:55-14:40 | Presidential Symposium | |||
| The Evolution of Acute Leukemia Diagnostics and Its Place in Treatment Elizabeth Macintyre, France |
||||
| 14:40-16:10 | [MS01] MOU Country Session -Lymphoid Malignancy- (14:40-15:40) |
[SS07] Benign Hematology | [ES04] Myeloproliferative Neoplasm | |
| Outcome of Autologous Transplant in T-Cell Lymphoma: Experience of NIHBT in Vietnam Nguyen Vu Bao Anh, Vietnam |
Novel Treatment for ITP Cindy Neunert, USA |
The Role of Interferon for the Treatment of MPNs Seug Yun Yoon, Korea |
||
| Subcutaneous Panniculitis-like T-Cell Lymphoma Udomsak Bunworasate, Thailand |
Recent Understandings of Congenital Neutropenia Hyoung Soo Choi, Korea |
Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelofibrosis Patients in JAK Inhibitor Era Sung-Yong Kim, Korea |
||
| Update of Extranodal NK/T-cell Lymphoma: Treatment and Biology Seok Jin Kim, Korea |
Non-Factor Approach including Emicizumab Keiji Nogami, Japan |
To Modify the Disease Course of MPNs Sung-Eun Lee, Korea |
||
| 16:10-16:25 | Break | |||
| 16:25-17:55 | [JS05] EHA-KSH Joint Symposium 2 -Clinical-Translational- (16:25-18:05) |
[SS08] Supportive Care | [SS09] Bone Marrow Failure Syndrome | |
| Immunotherapy in AML: From alloSCT towards CAR-T Cell Therapy Charles Craddock, UK |
Improve Palliative Care and Outcomes in Low- and Middle-Income Countries Scott Howard, USA |
Challenges in the Diagnosis of Bone Marrow Failure Syndromes: The Role of Genetic Panels? Ghulam J Mufti, UK |
||
| The Emerging Role of MRD in AML Gert Ossenkoppele, The Netherlands |
Renal Supportive Care and Palliative Care in Patients with Hematologic Diseases Chung Hee Baek, Korea |
Clonal Hematopoesis in Bone Marrow Failure Austin G Kulasekararaj, UK |
||
| Therapeutic Potential of ATO to Overcome Resistance of Bcl-2 Inhibitor in AML Jieun Jang, Korea |
Vaccinations before/after Biologic Agents in Patients with Hematologic Malignancies Wan Beom Park, Korea |
Current Guidelines for the Treatment of Acquired Aplastic Anemia in Japan: An Immune Marker-Based Approach Shinji Nakao, Japan |
||
| MRD in AML Byung Sik Cho, Korea |
||||
| Date | Saturday, April 3, 2021 | ||
|---|---|---|---|
| Room | ROOM 1 | ROOM 2 | ROOM 3 |
| 07:30-08:30 | Business Meeting | ||
| 08:30-09:00 | Working Party Reports | ||
| 09:00-10:30 | [SS10] Immunotherapy/Transplantation | [SS11] Pediatric Disease | [SS12] T-Cell Lymphoma /HD |
| CD8+ TILs Bifurcate Divergent Differentiation Trajectory toward TEMRA in Non-Small Cell Lung Cancer Patients, Deciphering an Immunogenicity of Tumor Antigens Jae-Ho Cho, Korea |
Juvenile Myelomonocytic Leukemia: Learning from Patients in a World Without Walls Mignon Loh, USA |
PD-L1 and NK/T-Cell Lymphoma Won Seog Kim, Korea |
|
| Immunosenescent Characteristics of T Cells in Young Patients Following Haploidentical HSCT from Parental Donors Won-Woo Lee, Korea |
Sirolimus Therapy for Vascular Anomaly Keon Hee Yoo, Korea |
Novel Agents for PTCL Francine Foss, USA |
|
| CAR T Cells for AML: Lessons from the Clinic Saar Gill, USA |
Langerhans Cell Histiocytosis 2021: New Insights and Opportunities Carl Allen, USA |
A Translational Research in Angioimmunoblastic T-Cell Lymphoma: From Genome to Bedside Sakata-Yanagimoto Mamiko, Japan |
|
| 10:30-11:15 | Plenary Lecture III - Genomics in Hematologic Malignancies | ||
| Latest Treatment Developments in Multiple Myeloma Nikhil Munshi, USA |
|||
| 11:15-11:30 | Coffee Break | ||
| 11:30-12:10 | [SY08] Satellite Symposium 8 | [SY09] Satellite Symposium 9 | [SY10] Satellite Symposium 10 |
| Updated ASH ITP Treatment Guideline and Its Implications for Clinical Practice Waleed Ghanima, Norway
Sponsored by
|
The Efficacy and Safety of Pegfilgrastim and PEGylated G-CSFs: Real World Experience in DLBCL Yong Park, Korea
Sponsored by
|
Real-World Outcomes and Factors Impacting Treatment Choice in Relapsed/Refractory Multiple Myeloma Ji Hyun Lee, Korea
Sponsored by
|
|
| 12:10-12:55 | Award Ceremony & Closing | ||
